Dechra Pharmaceuticals

Dechra Pharmaceuticals PLC
Public (LSE: DPH)
Industry Pharmaceuticals
Founded 1997
Headquarters Northwich, United Kingdom
Key people
 Michael Redmond, (Chairman)
Ian Page, (CEO)
Revenue £359.3 million (2017)[1]
£81.3 million (2017)[1]
£26.1 million (2017)[1]
Website www.dechra.com

Dechra Pharmaceuticals PLC is an England-based manufacturer of veterinary products. It is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.

History

The Company was founded in 1997 by way of a management buy-out from Lloyds Chemists.[2] It was first listed on the London Stock Exchange in 2000.[2] In 2007 it bought VetXX, a Danish veterinary products business, for £62m.[3] It sold its veterinary services business to US-firm, Patterson Companies, for £87.5m in July 2013 in order to focus on its higher margin manufacturing business.[4]

Operations

The Company sells pharmaceuticals - mainly for dogs, cats, equine and food producing animals; products include Vetoryl for Cushing's disease in dogs and Felimazole for hyperthyroidism in cats. It is organised into two divisions: European Pharmaceuticals and US Pharmaceuticals.[5]

See also

References

  1. 1 2 3 "Annual Report 2017" (PDF). Retrieved 25 March 2018.
  2. 1 2 Montague Private Equity announces sale of VetXX
  3. ↑ "Dechra Pharma to buy VetXX for 61.7 mln stg". Reuters. Retrieved 28 March 2015.
  4. ↑ "Dechra sells up". Investors Chronicle. 11 July 2013. Retrieved 16 March 2014.
  5. ↑ "Dechra Pharmaceuticals PLC". dechraplc.com. Retrieved 28 March 2015.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.